← Leaderboards
Jordana B. Cohen
University Of Pennsylvania
$7,481,237
Attributed
$10,708,086
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,708,086 · 5
By mechanism
R01$9,618,570 · 3
K23$944,710 · 1
F32$144,806 · 1
Top collaborators
- Adam P Bress6 shared
- Julio Alonso Chirinos Medina4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Rachel Kelz$7,254,027
- Daniel Benjamin Horton$8,748,567
- Julio Alonso Chirinos Medina$12,868,016
- Gina Hong$1,017,447
- Hans-Peter Kohler$18,145,090
Others in their field
Top investigators on “Risk Factors”
- Jeffrey P Krischer · University Of South Florida$393,499,152
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard Webby · St. Jude Children'S Research Hospital$180,330,417
- John M Lachin · George Washington University$139,236,598
Research focus
Risk FactorsPublic HealthPharmaceutical PreparationsQuality Of LifeHypertensionHeart DiseasesElectronic Health RecordHeart FailurePhysiologicalPharmacoepidemiologyCardiovascular DiseasesAlzheimer&AposAntihypertensive AgentsMortalityAffectUnited StatesKidneyKidney DiseasesBaseHemodynamicsDesignFunctional DisorderPrevalenceChronic Kidney Failure
Grant awards (22)
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$759,634
R01 · FY2025 · HL
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$741,675
R01 · FY2025 · AG · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$167,518
R01 · FY2025 · AG · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$763,579
R01 · FY2024 · AG · contact PI
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$759,344
R01 · FY2024 · HL
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)$622,706
R01 · FY2024 · HL · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$83,579
R01 · FY2024 · AG · contact PI
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$792,262
R01 · FY2023 · HL
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$774,072
R01 · FY2023 · AG · contact PI
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)$661,671
R01 · FY2023 · HL · contact PI
Informing optimal first-line antihypertensive therapy: A rigorous comparative effectiveness analysis of ARBs vs. ACEIs on long-term risk of dementia, cancer, heart disease, and quality of life$808,711
R01 · FY2022 · AG · contact PI
Cardiovascular Risk, Vascular and Kidney Damage in COVID-19 Survivors$803,324
R01 · FY2022 · HL
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)$638,024
R01 · FY2022 · HL · contact PI
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)$638,024
R01 · FY2021 · HL · contact PI
Blockade of calcium channels and beta adrenergic receptors for physiologic abnormalities in heart failure with preserved ejection fraction (BLOCK HFpEF)$604,447
R01 · FY2020 · HL · contact PI
Management of hypertension in obesity: Antihypertensive class effects, blood pressure control, and renal and cardiac outcomes$188,974
K23 · FY2020 · HL · contact PI
Management of hypertension in obesity: Antihypertensive class effects, blood pressure control, and renal and cardiac outcomes$188,974
K23 · FY2019 · HL · contact PI
Management of hypertension in obesity: Antihypertensive class effects, blood pressure control, and renal and cardiac outcomes$188,974
K23 · FY2018 · HL · contact PI
Management of hypertension in obesity: Antihypertensive class effects, blood pressure control, and renal and cardiac outcomes$188,894
K23 · FY2017 · HL · contact PI
Management of hypertension in obesity: Antihypertensive class effects, blood pressure control, and renal and cardiac outcomes$188,894
K23 · FY2016 · HL · contact PI
Obesity, renin-angiotensin-aldosterone blockade, and chronic kidney disease$69,860
F32 · FY2015 · DK · contact PI
Obesity, renin-angiotensin-aldosterone blockade, and chronic kidney disease$74,946
F32 · FY2014 · DK · contact PI